🇺🇸 FDA

Intelligence · Clinical Pipeline

First People's Hospital Pipeline

All ClinicalTrials.gov programs at First People's Hospital — phase, modality, and trial IDs.

Programs
1,136

Quick answer

First People's Hospital has 1,136 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. JAK Inhibitor

    The First People's Hospital of Lianyungang

    Dermatomyositis, Adult Type

    approved small molecule active

    1 trial

  2. KANG FU PEN

    The First People's Hospital of Lianyungang

    Cervical Cancer

    approved small molecule active

    1 trial

  3. Keverprazan

    The First People's Hospital of Lianyungang

    H. Pylori Infection

    approved small molecule active

    1 trial

  4. Lecanemab 10 mg/kg

    The First People's Hospital of Lianyungang

    Alzheimer s Disease

    approved small molecule active

    1 trial

  5. Levocarnitine Injection

    The First People's Hospital of Lianyungang

    Renal Dialysis

    approved small molecule completed

    1 trial

  6. Levothyroxine

    The First People's Hospital of Lianyungang

    Heart Failure

    approved small molecule active

    1 trial

  7. Live Combined Bifidobacterium and Lactobacillus

    The First People's Hospital of Lianyungang

    Functional Constipation

    approved small molecule active

    1 trial

  8. Longidaza

    The First People's Hospital of Lianyungang

    Bacterial Vaginosis

    approved small molecule active

    1 trial

  9. Low dose Oliceridine

    The First People's Hospital of Lianyungang

    Oliceridine

    approved small molecule active

    1 trial

  10. Maggot debridement therapy

    The First People's Hospital of Lianyungang

    Diabetic Foot Ulcers

    approved other active

    1 trial

  11. Mesalazine

    The First People's Hospital of Lianyungang

    Ulcerative Colitis, Unspecified

    approved small molecule active

    1 trial

  12. Methimazole

    The First People's Hospital of Lianyungang

    Graves Disease

    approved small molecule active

    1 trial

  13. Minocycline

    The First People's Hospital of Lianyungang

    Ischemic Stroke, Acute

    approved small molecule active

    2 trials

  14. Montelukast

    The First People's Hospital of Lianyungang

    Sinusitis

    approved small molecule completed

    1 trial

  15. Nerve block with liposomal bupivacaine and intravenous analgesia

    The First People's Hospital of Lianyungang

    Liposomal Bupivacaine

    approved other active

    1 trial

  16. Nifedipine GITS

    The First People's Hospital of Lianyungang

    Hypertension

    approved small molecule active

    1 trial

  17. Nocardia rubra Cell Wall Skeleton

    The First People's Hospital of Lianyungang

    Diabetic Foot Ulcer

    approved small molecule active

    1 trial

  18. Optimal hypoglycemic treatment

    The First People's Hospital of Lianyungang

    Type2 Diabetes

    approved other active

    1 trial

  19. Ornithine aspartate granule

    The First People's Hospital of Lianyungang

    Non-alcoholic Fatty Liver Disease

    approved small molecule completed

    1 trial

  20. PCIA group

    The First People's Hospital of Lianyungang

    Postoperative Pain

    approved other active

    1 trial

  21. PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    approved small molecule active

    1 trial

  22. PEG-somatropin

    The First People's Hospital of Lianyungang

    Growth Hormone Deficiency

    approved mab active

    1 trial

  23. Parecoxib

    The First People's Hospital of Lianyungang

    Emergence Delirium

    approved small molecule active

    1 trial

  24. Parecoxib

    The First People's Hospital of Lianyungang

    Postoperative Pain Management, Pain Threshold, Shoulder Pain, Laparoscopies

    approved small molecule completed

    1 trial

  25. Pegylated liposomal doxorubicin

    The First People's Hospital of Lianyungang

    Breast Cancer

    approved small molecule active

    1 trial

  26. Pharmacotherapy

    The First People's Hospital of Lianyungang

    Diabetes Mellitus, Type 2

    approved small molecule active

    1 trial

  27. Pramipexole

    The First People's Hospital of Lianyungang

    Restless Legs Syndrome

    approved small molecule terminated

    1 trial

  28. Prothrombin Complex Concentrate, Human

    The First People's Hospital of Lianyungang

    Cardiac Surgical Procedures

    approved small molecule active

    1 trial

  29. Raltitrexed

    The First People's Hospital of Lianyungang

    Head and Neck Squamous Cell Carcinoma

    approved small molecule active

    1 trial

  30. Realgar-Indigo Naturalis Formulation Combined with Anlotinib

    The First People's Hospital of Lianyungang

    Platinum-resistant Ovarian Cancer (PROC)

    approved small molecule active

    1 trial

  31. Recaticimab

    The First People's Hospital of Lianyungang

    STEMI - ST Elevation Myocardial Infarction

    approved small molecule active

    1 trial

  32. Recaticimab and Statin

    The First People's Hospital of Lianyungang

    Intracranial Atherosclerosis

    approved small molecule active

    1 trial

  33. Recombinant Human Adenovirus Type 5 injection

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    approved small molecule active

    1 trial

  34. Recombinant Staphylokinase

    The First People's Hospital of Lianyungang

    ST-segment Elevation Myocardial Infarction (STEMI)

    approved small molecule completed

    1 trial

  35. Recombinant Staphylokinase

    The First People's Hospital of Lianyungang

    Acute Myocardial Infarction

    approved small molecule completed

    1 trial

  36. Recombinant staphylokinase

    The First People's Hospital of Lianyungang

    ST Elevation Myocardial Infarction

    approved small molecule active

    1 trial

  37. Remimazolam Besylate for Injection

    The First People's Hospital of Lianyungang

    Thoracic Surgery

    approved small molecule active

    1 trial

  38. Resveratrol

    The First People's Hospital of Lianyungang

    Pancreatitis, Acute

    approved small molecule active

    1 trial

  39. Rifaximin

    The First People's Hospital of Lianyungang

    IBS - Irritable Bowel Syndrome

    approved small molecule active

    1 trial

  40. Rituximab

    The First People's Hospital of Lianyungang

    Hemophagocytic Lymphohistiocytosis

    approved small molecule active

    1 trial

  41. Ropivacaine

    The First People's Hospital of Lianyungang

    Radius Fractures

    approved small molecule completed

    1 trial

  42. Ropivacaine

    The First People's Hospital of Lianyungang

    End Stage Renal Disease (ESRD)

    approved small molecule active

    1 trial

  43. Rosuvastatin

    The First People's Hospital of Lianyungang

    Hyperlipidemia

    approved small molecule active

    1 trial

  44. Rucacuzumab plus standard therapy

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke AIS

    approved small molecule active

    1 trial

  45. Ruxolitinib

    The First People's Hospital of Lianyungang

    Safety and Efficacy

    approved small molecule active

    2 trials

  46. S-1

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    approved small molecule active

    1 trial

  47. S-ketamine & Ropivacaine

    The First People's Hospital of Lianyungang

    Postoperative Analgesia

    approved small molecule active

    1 trial

  48. SGLT2 inhibitor

    The First People's Hospital of Lianyungang

    Type2 Diabetes

    approved small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does First People's Hospital have?

1,136 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.